US EditionAbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
UNITED STATES, JUN 30 – AbbVie will pay up to $2.1 billion to acquire Capstan's in vivo CAR-T platform and lead candidate CPTX2309, advancing scalable treatments for B cell-driven autoimmune diseases.
- On June 30, 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics, including its lead program CPTX2309 and proprietary tLNP platform.
- AbbVie sought to expand its immunology pipeline as Humira faces biosimilar competition and Capstan develops novel in vivo CAR-T therapies for autoimmune diseases.
- CPTX2309 delivers mRNA via lipid nanoparticles to reprogram T cells to deplete pathogenic B cells without lymphodepletion, with a Phase 1 trial enrolling healthy volunteers underway.
- AbbVie will provide up to $2.1 billion in cash upfront as part of the acquisition, and company leadership highlighted that initial Phase 1 results demonstrate rapid and substantial B-cell depletion, supporting the clinical potential of CPTX2309.
- The acquisition positions AbbVie to develop scalable, disease-modifying immunology therapies with in vivo cell engineering, potentially reshaping autoimmune disease treatment.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
MedCity NewsReposted by 
Dealbreaker
DealbreakerAbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.
Coverage Details
Total News Sources20
Leaning Left1Leaning Right0Center7Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
13%
C 88%
Factuality
To view factuality data please Upgrade to Premium
